期刊文献+

他汀类药物对冠状动脉造影围手术期造影剂肾病的预防研究 被引量:4

Role of statins in prevention of contrast-induced nephropathy after coronary arteriography-guided perioperation
下载PDF
导出
摘要 目的分析经皮冠状动脉造影患者接受他汀类药物治疗后,围手术期前后早期肾损伤标记物水平的变化,探讨他汀类药物在预防造影剂肾病的作用。方法选择行冠状动脉造影的患者1 26例,随机分为对照组61例和他汀类药物治疗组(他汀组)65例,检测2组患者围手术期前后血肌酐、早期肾损伤标记物血清胱抑素C及高敏C反应蛋白水平的变化,并进行比较。结果他汀组和对照组术后血清高敏C反应蛋白较术前明显升高[(4.0±0.5)mg/L vs(2.2±0.6)mg/L,(5.2±0.9)mg/L vs(2.1±0.4)mg/L,P<0.01]。他汀组术后血清胱抑素C水平较对照组明显降低[(1.3±0.2)mg/Lvs(1.7±0.4)mg/L,P<0.01]。结论造影剂肾病可能与造影剂介导的炎性反应相关,他汀类药物可能通过拮抗炎性反应及氧化应激机制等预防该病的发生。 Objective To study the role of statins in prevention of contrast-induced nephropathy (CIN) by analyzing the changes of early renal injury biomarker levels in patients who underwent coronary arteriography(CAG)-gnided operation after teatment with statins. Methods One hun- dred and twenty-six patients who underwent CAG-guided operation were divided into control group(n = 61) and statin treatment group (n = 65). Their serum levels of creatinine, cystatin C (Cys C),an early renal injury biomarker,and high sensitivity C-reactive protein(hs-CRP) were measured and compared. Results The hs-CRP and Cys C levels were significantly higher in statin treatment group and control group after operation than before operation(4.0±0.5 mg/L vs 2.2± 0.6 mg/L,5.2±0.9 mg/L vs 2.1±0.4 mg/L,P〈0.01) ,while the Cys C level was significantly lower in statin treatment group than in control group(1.3±0.2 mg/L vs 1. 74-0.4 mg/L,P〈 0. 01). Conclusion CIN may be related with contrast-induced inflammatory reactions. Satains prevent its occurrence possibly by antagonizing inflammatory reactions and oxidative stress.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2012年第7期722-724,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 冠状血管造影术 手术期间 造影剂 肾病 降血脂药 C反应蛋白质 coronary angiography intraoperative period contrast media nephrosis antilipemic agents C-reactive protein
  • 相关文献

参考文献10

  • 1Gupta R ,Birnbaum Y, Uret sky BF. The renal patient with coronary artery disease : Current concepts and dilemmas. J Am Coil Cardiol, 2004,44 : 1343-1353.
  • 2McCullough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast induced nephropathy. Am J Cardiol, 2006,98 : 5K-13K.
  • 3Thomsen HS. European Society of Urogenital Radiology (ESUR) guidelines on the safe use of iodinated contrast media. Eur J Radiol, 2006,60:307-313.
  • 4Briguori C,Visconti G,Rivera NV,et al. Cystatin C and con trast-induced acute kidney injury. Circulation, 2010,121 .. 2117- 2122.
  • 5Chong E,Poh KK,Liang S,et al. Risk factors and clinical out comes of contrast induced nephropathy after percutaneous coronary intervention in patients with normal serum creati- nine. Ann Acad Med Singapore, 2010,39:374-380.
  • 6Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med,2011,39:1871-1878.
  • 7Zhao JL,Yang YJ,Zhang YH,et al. Effect of statins on con- trast induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. International Journal of Cardiology,2008,126:435-436.
  • 8Patti G, Nusca A, Ch ello M, et al. Usefulness of statin pre treatment to prevent contrast induced nephropathy andto im prove long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008,101:279-285.
  • 9Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revaseularization. Eur Heart J, 2010,31 : 2501-2555.
  • 10Stacul F, Adam A, Becker CR, et al. Strategics to reduce the risk of contrast induced nephropathy. Am J Cardiol, 2006,98: 59K-77K.

同被引文献78

  • 1邹古明,颜红兵.造影剂肾病的诊断与治疗现状[J].中国介入心脏病学杂志,2005,13(3):194-196. 被引量:78
  • 2成威,周胜华,张铭,李旭平.阿托伐他汀对高血压肾病蛋白尿及C-反应蛋白和白介素-6的影响[J].高血压杂志,2005,13(12):767-770. 被引量:43
  • 3Mitchell AM,Jones AE, Tumlin JA, et al. Incidence of con- trast-induced nephropathy after contrast enhanced computed tomography in the outpatient setting. Cli J Am Soc Nephrol,2010,5:4-9.
  • 4Karlsberg RP, Dohad SY, Sheng R. Contrastqnduced acute kidney injury (CI-AKI) following intra arterial administration of iodinated contrast media. J Nephrol, 2010,23 :658-666.
  • 5Chuang FR, Chen TC, Wang IK, et al. Comparison of iodix anol and iohexol in patients undergoing intravenous pyelogra phy:a prospective controlled study. Renal Failure, 2009,31 :181 -188.
  • 6Nusca A, Melfi R, Patti G, et al. Statin loading before percuta- neous coronary intervention:proposed mechanisms and appli- cations. Future Cardiology, 2010,6 : 579-589.
  • 7Bolognese L, Falsini G, Schwenke C, et al. Impact of iso osmolar versus low-osmolar contrast agents on contrast-in- duced nephropathy and tissue reperfusion in unselected pa tients with ST segment elevation myocardial infarction under going primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angio plasty for Acute Myocardial Infarction[CONTRAST AMI] Trial). Am J Cardiol,2012,109:67 -74.
  • 8Perrin T, Descombes E, Cook S. Contrast-induced nephropa- thy in invasive cardiology. Swiss Med Wkly, 2012, 142: w13608.
  • 9Patti G, Ricottini E, Nusca A, et al. Short term, high dose Atorvastatin pretreatment to prevent contrast induced ne- phropathy in patients with acute coronary syndromes under- going pereutaneous coronary intervention from the ARMYDA- CIN trial. Am J Cardiol, 2011,108 : 1-7.
  • 10Ozhan H,Erden I,Ordu S, et al. Efficacy of short term high- dose atorvastatin for prevention of contrast induced nephrop athy in patients undergoing coronary angiography. Angiology, 2010,61:711- 714.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部